Bio

Bio


Jennifer K. Chen, M.D., is a Clinical Associate Professor of Dermatology and Assistant Chief of Medical Dermatology. She co-directs the medical student sub-internship program. She completed medical school at Johns Hopkins University, residency at Johns Hopkins and University of California, Irvine, and completed a Howard Hughes Fellowship at Stanford University. Her clinical interests include complex medical dermatology, skin cancer, inpatient dermatology, atopic dermatitis, and contact dermatitis.

Clinical Focus


  • Dermatology
  • Contact Dermatitis
  • Psoriasis
  • Skin Cancers
  • Atopic Dermatitis
  • Eczema

Academic Appointments


Professional Education


  • Internship:Johns Hopkins Bayview Hospital Internal Medicine Residency (2010) MD
  • Board Certification: Dermatology, American Board of Dermatology (2013)
  • Undergraduate Degree, University of California, Berkeley, CA (2003)
  • Medical Education:Johns Hopkins University School of Medicine (2009) MD
  • Fellowship, Howard Hughes Medical Institute Fellowship, Stanford University School of Medicine, Dermatology (2009)
  • Residency:University of California Irvine (2013) CA
  • Board Certification, Dermatology, American Board of Dermatology (2013)

Publications

All Publications


  • Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10. JAMA dermatology Noe, M. H., Rosenbach, M., Hubbard, R. A., Mostaghimi, A., Cardones, A. R., Chen, J. K., Cotliar, J., Davis, M. D., Dominguez, A., Fox, L. P., Hughey, L. C., Kaffenberger, B. H., Kroshinsky, D., Kwong, B. Y., Miller, D. D., Musiek, A., Ortega-Loayza, A. G., Sharon, V. R., Shinkai, K., Summers, E. M., Wanat, K. A., Wetter, D. A., Worswick, S., Margolis, D. J., Gelfand, J. M., Micheletti, R. G. 2019

    Abstract

    Importance: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a spectrum of severe mucocutaneous drug reaction associated with significant morbidity and mortality. A previously developed SJS/TEN-specific severity-of-illness model (Score of Toxic Epidermal Necrolysis [SCORTEN]) has been reported to overestimate and underestimate SJS/TEN-related in-hospital mortality in various populations.Objective: To derive a risk prediction model for in-hospital mortality among patients with SJS/TEN and to compare prognostic accuracy with the SCORTEN model in a multi-institutional cohort of patients in the United States.Design, Setting, and Participants: Data from a multicenter cohort of patients 18 years and older treated for SJS/TEN between January 1, 2000, and June 1, 2015, were obtained from inpatient consult databases and electronic medical record systems at 18 medical centers in the United States as part of the Society for Dermatology Hospitalists. A risk model was derived based on data from 370 of these patients. Model discrimination (calculated as area under the receiver operating characteristic curve [AUC]) and calibration (calculated as predicted vs observed mortality, and examined using the Hosmer-Lemeshow goodness-of-fit statistic) were assessed, and the predictive accuracy was compared with that of SCORTEN. All analysis took place between December 2016 and April 2018.Main Outcomes and Measures: In-hospital mortality.Results: Among 370 patients (mean [SD] age 49.0 [19.1] years; 195 [52.7%] women), 54 (15.14%) did not survive to hospital discharge. Five covariates, measured at the time of admission, were independent predictors of in-hospital mortality: age in years (odds ratio [OR], 1.05; 95% CI, 1.02-1.07), body surface area (BSA) in percentage of epidermal detachment (OR, 1.02; 95% CI, 1.01-1.04), serum bicarbonate level below 20 mmol/L (OR, 2.90; 95% CI, 1.43-5.88), active cancer (OR, 4.40; 95% CI, 1.82-10.61), and dialysis prior to admission (OR, 15.94; 95% CI, 3.38-66.30). A severity-of-illness score was calculated by taking the sum of 1 point each for age 50 years or older, epidermal detachment greater than 10% of BSA, and serum bicarbonate level below 20 mmol/L; 2 points for the presence of active cancer; and 3 points for dialysis prior to admission. The score was named ABCD-10 (age, bicarbonate, cancer, dialysis, 10% BSA). The ABCD-10 model showed good discrimination (AUC, 0.816; 95% CI, 0.759-0.872) and calibration (Hosmer-Lemeshow goodness of fit test, P=.03). For SCORTEN, on admission, the AUC was 0.827 (95% CI, 0.774-0.879) and was not significantly different from that of the ABCD-10 model (P=.72).Conclusions and Relevance: In this cohort of patients with SJS/TEN, ABCD-10 accurately predicted in-hospital mortality, with discrimination that was not significantly different from SCORTEN. Additional research is needed to validate ABCD-10 in other populations. Future use of a new mortality prediction model may provide improved prognostic information for contemporary patients, including those enrolled in observational studies and therapeutic trials.

    View details for PubMedID 30840032

  • Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States (vol 138, pg 2315, 2018) JOURNAL OF INVESTIGATIVE DERMATOLOGY Micheletti, R. G., Chiesa-Fuxench, Z., Noe, M. H., Stephen, S., Aleshin, M., Agarwal, A., Boggs, J., Cardones, A. R., Chen, J. K., Cotliar, J., Davis, M. P., Dominguez, A., Fox, L. P., Gordon, S., Hamrick, R., Ho, B., Hughey, L. C., Jones, L. M., Kaffenberger, B. H., Kindley, K., Kroshinsky, D., Kwong, B. Y., Miller, D. D., Mostaghimi, A., Musiek, A., Ortega-Loayza, A. G., Patel, R., Posligua, A., Rani, M., Saluja, S., Sharon, V. R., Shinkai, K., St John, J., Strickland, N., Summers, E. M., Sun, N., Wanat, K. A., Wetter, D. A., Worswick, S., Yang, C., Margolis, D. J., Gelfand, J. M., Rosenbach, M. 2019; 139 (2): 495–96
  • Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States JOURNAL OF INVESTIGATIVE DERMATOLOGY Micheletti, R. G., Chiesa-Fuxench, Z., Noe, M. H., Stephen, S., Aleshin, M., Agarwal, A., Boggs, J., Cardones, A. R., Chen, J. K., Cotliar, J., Davis, M. P., Dominguez, A., Fox, L. P., Gordon, S., Hamrick, R., Ho, B., Hughey, L. C., Jones, L. M., Kaffenberger, B. H., Kindley, K., Kroshinsky, D., Kwong, B. Y., Miller, D. D., Mostaghimi, A., Musiek, A., Ortega-Loayza, A. G., Patel, R., Posligua, A., Rani, M., Saluja, S., Sharon, V. R., Shinkai, K., St John, J., Strickland, N., Sun, N., Wanat, K. A., Wetter, D. A., Worswick, S., Yang, C., Margolis, D. J., Gelfand, J. M., Rosenbach, M. 2018; 138 (11): 2315–21

    Abstract

    Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a rare, severe mucocutaneous reaction with few large cohorts reported. This multicenter retrospective study included patients with SJS/TEN seen by inpatient consultative dermatologists at 18 academic medical centers in the United States. A total of 377 adult patients with SJS/TEN between January 1, 2000 and June 1, 2015 were entered, including 260 of 377 (69%) from 2010 onward. The most frequent cause of SJS/TEN was medication reaction in 338 of 377 (89.7%), most often to trimethoprim/sulfamethoxazole (89/338; 26.3%). Most patients were managed in an intensive care (100/368; 27.2%) or burn unit (151/368; 41.0%). Most received pharmacologic therapy (266/376; 70.7%) versus supportive care alone (110/376; 29.3%)-typically corticosteroids (113/266; 42.5%), intravenous immunoglobulin (94/266; 35.3%), or both therapies (54/266; 20.3%). Based on day 1 SCORTEN predicted mortality, approximately 78 in-hospital deaths were expected (77.7/368; 21%), but the observed mortality of 54 patients (54/368; 14.7%) was significantly lower (standardized mortality ratio = 0.70; 95% confidence interval = 0.58-0.79). Stratified by therapy received, the standardized mortality ratio was lowest among those receiving both steroids and intravenous immunoglobulin (standardized mortality ratio = 0.52; 95% confidence interval 0.21-0.79). This large cohort provides contemporary information regarding US patients with SJS/TEN. Mortality, although substantial, was significantly lower than predicted. Although the precise role of pharmacotherapy remains unclear, co-administration of corticosteroids and intravenous immunoglobulin, among other therapies, may warrant further study.

    View details for PubMedID 29758282

  • Pediatric Baseline Patch Test Series: Pediatric Contact Dermatitis Workgroup DERMATITIS Yu, J., Atwater, A., Brod, B., Chen, J. K., Chisolm, S. S., Cohen, D. E., de la Feld, S., Gaspari, A. A., Martin, K., Montanez-Wiscovich, M., Sheehan, M., Silverberg, N., Lugo-Somolinos, A., Thakur, B. K., Watsky, K., Jacob, S. E. 2018; 29 (4): 206–12

    Abstract

    Allergic contact dermatitis is a challenging diagnostic problem in children. Although epicutaneous patch testing is the diagnostic standard for confirmation of contact sensitization, it is less used in children by dermatologists treating children, pediatric dermatologists, and pediatricians, when compared with adult practitioners.The aim of the study was to create and evaluate standardization of a pediatric patch test series for children older than 6 years.We surveyed dermatologists and allergists conducting epicutaneous patch testing in children attending the 2017 American Contact Dermatitis Society meeting held in Washington, DC. This was followed by discussion of collected data and consensus review by a pediatric contact dermatitis working group at the conference.A baseline pediatric patch test panel was established through working group consensus.

    View details for PubMedID 29933256

  • Metal Allergy: From Dermatitis to Implant and Device Failure edited by Chen, J. K., Thyssen, J. P. 2018
  • A Retrospective Study of 305 Cases of Angioimmunoblastic T-Cell Lymphoma with Emphasis on Rare Lymphoplasmacytic and Plasma Cell Proliferations Oak, J., Hoffmann, J. C., Chisholm, K. M., Chen, J., Zehnder, J., Arber, D. A., Natkunam, Y., Warnke, R., Ohgami, R. NATURE PUBLISHING GROUP. 2017: 367A–368A
  • A Retrospective Study of 305 Cases of Angioimmunoblastic T-Cell Lymphoma with Emphasis on Rare Lymphoplasmacytic and Plasma Cell Proliferations Oak, J., Hoffinann, J. C., Chisholm, K. M., Chen, J., Zehnder, J., Arber, D. A., Natkunam, Y., Warnke, R., Ohgami, R. NATURE PUBLISHING GROUP. 2017: 367A–368A
  • A Pragmatic Approach to Patch Testing Atopic Dermatitis Patients: Clinical Recommendations Based on Expert Consensus Opinion DERMATITIS Chen, J. K., Jacob, S. E., Nedorost, S. T., Hanifin, J. M., Simpson, E. L., Boguniewicz, M., Watsky, K. L., Lugo-Somolinos, A., Hamann, C. R., Eberting, C. L., Silverberg, J. I., Thyssen, J. P. 2016; 27 (4): 186-192

    Abstract

    Allergic contact dermatitis (ACD) may complicate the clinical course of atopic dermatitis (AD), and patch testing remains the criterion standard for diagnosing ACD. To date, there have been no guidelines or consensus recommendations on when and how to patch test individuals with AD. Failure to patch test when appropriate may result in overlooking an important and potentially curable complicating comorbidity. In this article, we present consensus recommendations regarding when to perform patch testing in the AD patient, best practices, and common pitfalls. Patch testing should be considered in AD patients with dermatitis that fails to improve with topical therapy; with atypical/changing distribution of dermatitis, or pattern suggestive of ACD; with therapy-resistant hand eczema in the working population; with adult- or adolescent-onset AD; and/or before initiating systemic immunosuppressants for the treatment of dermatitis. A suggested patch testing algorithm for AD patients is provided.

    View details for DOI 10.1097/DER.0000000000000208

    View details for PubMedID 27427820

  • Characterization of patients with clinical overlap of morphea and systemic sclerosis: A case series JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Chen, J. K., Chung, L., Fiorentino, D. F. 2016; 74 (6): 1272–74

    View details for PubMedID 27185438

  • Corticosteroids in Myositis and Scleroderma. Rheumatic diseases clinics of North America Postolova, A., Chen, J. K., Chung, L. 2016; 42 (1): 103-118

    Abstract

    Idiopathic inflammatory myopathies (IIMs) involve inflammation of the muscles and are classified by the patterns of presentation and immunohistopathologic features on skin and muscle biopsy into 4 categories: dermatomyositis, polymyositis, inclusion body myositis, and immune-mediated necrotizing myopathy. Systemic corticosteroid (CS) treatment is the standard of care for IIM with muscle and organ involvement. The extracutaneous features of systemic sclerosis are frequently treated with CS; however, high doses have been associated with scleroderma renal crisis in high-risk patients. Although CS can be effective first-line agents, their significant side effect profile encourages concomitant treatment with other immunosuppressive medications to enable timely tapering.

    View details for DOI 10.1016/j.rdc.2015.08.011

    View details for PubMedID 26611554

  • Erythematous Plaques on the Buttock JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION Tan, C. Z., Novoa, R., Chen, J. K. 2016; 315 (1): 79-80

    View details for DOI 10.1001/jama.2015.13562

    View details for PubMedID 26746461

  • Gold Contact Allergy: Clues and Controversies DERMATITIS Chen, J. K., Lampel, H. P. 2015; 26 (2): 69-77

    Abstract

    In 2001, gold was named Contact Allergen of the Year. More than a decade later, we continue to face several challenges in defining the role of gold in contact allergy. First, interpretation of gold reactions in the setting of epicutaneous patch testing may be difficult; in addition to being a common irritant, gold may be associated with significantly delayed and persistent reactions. Second, although gold compounds are commonly positive on patch testing, clinical relevance is relatively low and may be challenging to determine. Third, the complex interplay between gold and the human body is still poorly understood. In this review, we provide an overview of the literature concerning gold patch test positivity and present recommendations for epicutaneous patch testing with gold.

    View details for DOI 10.1097/DER.0000000000000101

    View details for Web of Science ID 000350912200003

    View details for PubMedID 25757078

  • Prehospital Use of Magnesium Sulfate as Neuroprotection in Acute Stroke NEW ENGLAND JOURNAL OF MEDICINE Saver, J. L., Starkman, S., Eckstein, M., Stratton, S. J., Pratt, F. D., Hamilton, S., Conwit, R., Liebeskind, D. S., Sung, G., Kramer, I., Moreau, G., Goldweber, R., Sanossian, N., FAST-MAG Investigators Coordinator 2015; 372 (6): 528–36

    Abstract

    Magnesium sulfate is neuroprotective in preclinical models of stroke and has shown signals of potential efficacy with an acceptable safety profile when delivered early after stroke onset in humans. Delayed initiation of neuroprotective agents has hindered earlier phase 3 trials of neuroprotective agents.We randomly assigned patients with suspected stroke to receive either intravenous magnesium sulfate or placebo, beginning within 2 hours after symptom onset. A loading dose was initiated by paramedics before the patient arrived at the hospital, and a 24-hour maintenance infusion was started on the patient's arrival at the hospital. The primary outcome was the degree of disability at 90 days, as measured by scores on the modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability).Among the 1700 enrolled patients (857 in the magnesium group and 843 in the placebo group), the mean (±SD) age was 69±13 years, 42.6% were women, and the mean pretreatment score on the Los Angeles Motor Scale of stroke severity (range, 0 to 10, with higher scores indicating greater motor deficits) was 3.7±1.3. The final diagnosis of the qualifying event was cerebral ischemia in 73.3% of patients, intracranial hemorrhage in 22.8%, and a stroke-mimicking condition in 3.9%. The median interval between the time the patient was last known to be free of stroke symptoms and the start of the study-drug infusion was 45 minutes (interquartile range, 35 to 62), and 74.3% of patients received the study-drug infusion within the first hour after symptom onset. There was no significant shift in the distribution of 90-day disability outcomes on the global modified Rankin scale between patients in the magnesium group and those in the placebo group (P=0.28 by the Cochran-Mantel-Haenszel test); mean scores at 90 days did not differ between the magnesium group and the placebo group (2.7 in each group, P=1.00). No significant between-group differences were noted with respect to mortality (15.4% in the magnesium group and 15.5% in the placebo group, P=0.95) or all serious adverse events.Prehospital initiation of magnesium sulfate therapy was safe and allowed the start of therapy within 2 hours after the onset of stroke symptoms, but it did not improve disability outcomes at 90 days. (Funded by the National Institute of Neurological Disorders and Stroke; FAST-MAG ClinicalTrials.gov number, NCT00059332.).

    View details for DOI 10.1056/NEJMoa1408827

    View details for Web of Science ID 000349143600007

    View details for PubMedID 25651247

    View details for PubMedCentralID PMC4920545

  • Hand Dermatitis: an Allergist's Nightmare CURRENT ALLERGY AND ASTHMA REPORTS Wold, L., Chen, J. K., Lampel, H. P. 2014; 14 (11)

    Abstract

    Hand dermatitis is a common skin complaint. We use our hands to explore our environment; subsequently, our hands are in frequent contact with potential allergens and irritants. Patients with hand dermatitis may present to their allergist with this complaint. Approaching the diagnosis and treatment of hand dermatitis can be challenging, as both internal and external factors may contribute to the overall condition. Furthermore, the differential diagnosis of hand dermatitis is broad and the cause often multifactorial. Obtaining a thorough history and performing a focused examination may help the clinician differentiate between multiple causes of hand dermatitis. Numerous treatment options exist for hand dermatitis, and new potential treatments are in development as well. We aim to provide the allergist with a streamlined toolkit for help in the diagnosis and management of hand dermatitis.

    View details for DOI 10.1007/s11882-014-0474-0

    View details for Web of Science ID 000343644500005

  • Erythematous lesions on the trunk and upper extremities. Journal of the American Academy of Dermatology Chen, J. K., Dann, F. 2014; 71 (3): e59-60

    View details for DOI 10.1016/j.jaad.2013.11.026

    View details for PubMedID 25128123

  • Drug-induced subacute cutaneous lupus erythematosus associated with doxorubicin JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Chen, J. K., Chen, T. S., Lim, P., Iqbal, M. 2012; 67 (6): E273-E275

    View details for DOI 10.1016/j.jaad.2012.05.021

    View details for Web of Science ID 000312131200015

    View details for PubMedID 23158635

  • An overview of clinical and experimental treatment modalities for port wine stains JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Chen, J. K., Ghasri, P., Aguilar, G., van Drooge, A. M., Wolkerstorfer, A., Kelly, K. M., Heger, M. 2012; 67 (2): 289-?

    Abstract

    Port wine stains (PWS) are the most common vascular malformation of the skin, occurring in 0.3% to 0.5% of the population. Noninvasive laser irradiation with flashlamp-pumped pulsed dye lasers (selective photothermolysis) currently comprises the gold standard treatment of PWS; however, the majority of PWS fail to clear completely after selective photothermolysis. In this review, the clinically used PWS treatment modalities (pulsed dye lasers, alexandrite lasers, neodymium:yttrium-aluminum-garnet lasers, and intense pulsed light) and techniques (combination approaches, multiple passes, and epidermal cooling) are discussed. Retrospective analysis of clinical studies published between 1990 and 2011 was performed to determine therapeutic efficacies for each clinically used modality/technique. In addition, factors that have resulted in the high degree of therapeutic recalcitrance are identified, and emerging experimental treatment strategies are addressed, including the use of photodynamic therapy, immunomodulators, angiogenesis inhibitors, hypobaric pressure, and site-specific pharmaco-laser therapy.

    View details for DOI 10.1016/j.jaad.2011.11.938

    View details for Web of Science ID 000306368600026

    View details for PubMedID 22305042

  • A comparison of world wide web resources for identifying medical information ACADEMIC RADIOLOGY Johnson, P. T., Chen, J. K., Eng, J., Makary, M. A., Fishman, E. K. 2008; 15 (9): 1165-1172

    Abstract

    To compare the utility of a search engine, Google, with other medical and non-medical, web-based resources for identifying specific medical information.This institutional review board-approved case cross-over study randomly assigned 89 medical student volunteers to use either Google or any other web-based resource (excluding Google) to research 10 advanced medical questions in a multiple choice exam. Primary outcome measures were resource efficiency (inversely related to number of links used to identify the correct answer for each question) and correctness (number of correct answers/total number of questions answered). For Google searches, the sites providing the information in question were also evaluated.The most frequently selected non-Google resources were Yahoo (n=531), Ask.com (n=110), and the interactive encyclopedia Wikipedia.com (n=74). Google was more efficient than all other resources (1.50 vs. 1.94 mean links, P<.0001), with no significant difference in correctness (97% [756/780] vs. 96% [747/780], P=.16). After a Google search, the four most common categories of sites that provided the correct answer were dictionary/encyclopedia sites, medical websites, National Library of Medicine resources, or journal websites. Yahoo was less efficient than Google (1.90 vs. 1.54 mean links, P<.0001). However, non-Google search engines were more efficient than web sites (eg, Wikipedia, medical websites) and PubMed (1.87 vs. 2.54 mean links, P=.0004).Google is an efficient web resource for identifying specific medical information, by guiding users to an array of medical resources.

    View details for DOI 10.1016/j.acra.2008.02.010

    View details for Web of Science ID 000259051700011

    View details for PubMedID 18692758